Is EINECS 204-031-2 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EINECS 204-031-2? Is EINECS 204-031-2 safe for nursing mother and child? Does EINECS 204-031-2 extracts into breast milk? Does EINECS 204-031-2 has any long term or short term side effects on infants? Can EINECS 204-031-2 influence milk supply or can EINECS 204-031-2 decrease milk supply in lactating mothers?

Not detected in infant serum

EINECS 204-031-2 is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal doses of up to 225 mg daily produce low levels in milk and breastfed infants' serum, and cause no adverse developmental consequences. EINECS 204-031-2 would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months.

Eight women who were receiving EINECS 204-031-2 for depression breastfed (extent not stated) their infants aged 0.13 to 12.5 months of age. Maternal dosages ranged from 25 to 225 mg daily (0.38 to 4.5 mg/kg daily). None of the infants had any noticeable adverse reactions.[3] A retrospective, case-control study of 15 women who breastfed while taking EINECS 204-031-2 for depression compared the neurocognitive outcomes of their infants to those in a group of 15 depressed mothers who had not taken an antidepressant during breastfeeding and another 36 women without depression. The mothers in the EINECS 204-031-2 group had taken dosages of 150 to 225 mg daily for 4 to 134 weeks during breastfeeding. Infants had been exposed to EINECS 204-031-2 in breast milk at times from 3 to 152 weeks of age and were assessed at 3 to 5 years of age. There was no evidence of negative effects on the infants' development using a number of rating scales.[6] Two infants were breastfed for 7 to 18 weeks during maternal use of EINECS 204-031-2. The drug was started when both infants were 8 weeks of age. One mother started with a dose of 50 mg daily that was increased to 100 mg daily; she took EINECS 204-031-2 for 33 weeks during breastfeeding. The other mother was taking 225 mg daily and nursed her infant for 25 weeks during breastfeeding. Formal testing indicated no adverse effects on infant development up to 30 months of age.[5]

Galactorrhea has been reported in one woman taking EINECS 204-031-2.[7] An observational study looked at outcomes of 2859 women who took an antidepressant during the 2 years prior to pregnancy. Compared to women who did not take an antidepressant during pregnancy, mothers who took an antidepressant during all 3 trimesters of pregnancy were 37% less likely to be breastfeeding upon hospital discharge. Mothers who took an antidepressant only during the third trimester were 75% less likely to be breastfeeding at discharge. Those who took an antidepressant only during the first and second trimesters did not have a reduced likelihood of breastfeeding at discharge.[8] The antidepressants used by the mothers were not specified. A retrospective cohort study of hospital electronic medical records from 2001 to 2008 compared women who had been dispensed an antidepressant during late gestation (n = 575) to those who had a psychiatric illness but did not receive an antidepressant (n = 1552) and mothers who did not have a psychiatric diagnosis (n = 30,535). Women who received an antidepressant were 37% less likely to be breastfeeding at discharge than women without a psychiatric diagnosis, but no less likely to be breastfeeding than untreated mothers with a psychiatric diagnosis.[9] None of the mothers were taking EINECS 204-031-2.